{"filings":[{"id":815676,"accession_number":"0001193125-26-254597","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2026-06-03T11:35:14+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Dyne Therapeutics completes enrollment of ACHIEVE registrational cohort with 71 DM1 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registrational expansion cohort (REC) enrolled 71 participants; topline data expected Q1 2027.","Potential BLA submission for U.S. Accelerated Approval in Q3 2027 using REC and MAD/LTE data.","Potential U.S. launch of z-basivarsen in H1 2028 if FDA grants Priority Review.","Also pursuing approval pathways outside U.S. for DM1 therapy.","ACHIEVE primary endpoint: change in middle finger myotonia via vHOT at 6 months vs placebo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-06-03","daily_digest_url":"/daily/2026-06-03","daily_digest_rank":10},{"id":95755,"accession_number":"0001193125-26-215720","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Q1 net loss $120.9M; BLA for z-rostudirsen on track for Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $120.9M ($0.73 per share) vs $115.4M ($1.05) in Q1 2025.","Cash and marketable securities $972.2M; expected to fund operations into Q1 2028.","R&D expenses $100.9M (down from $106.4M); G&A $24.4M (up from $15.9M) due to launch prep.","Positive pre-BLA meeting with FDA; BLA submission for z-rostudirsen in exon 51 DMD on track for Q2 2026.","ACHIEVE trial enrollment target of 60 participants reached; Phase 3 HARMONIA trial for z-basivarsen in DM1 initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109043,"accession_number":"0001193125-26-084207","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne posts FY2025 net loss $446M; z-rostudirsen BLA submission on track for Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $446.2M ($3.47/share) for FY2025 vs $317.4M ($3.37/share) in FY2024; R&D expense $398.3M.","Cash $1.1B at Dec 31, 2025; expected runway into Q1 2028.","Z-rostudirsen in DMD met primary endpoint: dystrophin 5.46% of normal (p<0.0001); BLA submission planned Q2 2026.","Z-basivarsen in DM1: enrollment completion of registrational cohort expected Q2 2026; topline data Q1 2027.","Advancing four DMD exon-skipping candidates (exons 53, 45, 44, 55) into IND-enabling studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109042,"accession_number":"0001193125-26-009782","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Dyne Therapeutics reports preliminary cash of ~$1.1B as of Dec 31, 2025","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Preliminary unaudited cash, cash equivalents and marketable securities of approximately $1.1 billion as of December 31, 2025.","Figure is a management estimate subject to completion of financial closing procedures; no audit or review by independent accountants.","Company also presented at J.P. Morgan Healthcare Conference on January 12, 2026; presentation content was not detailed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125508,"accession_number":"0001193125-25-329511","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Dyne Therapeutics elects Vikram Karnani as Class II director effective Dec 22, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vikram Karnani elected to the Board as an independent director; term expires at 2028 Annual Meeting.","Received option to purchase 59,665 shares at $20.78/share, vesting monthly over three years.","Will receive annual cash compensation of $45,000 plus standard equity grants under non-employee director plan.","No family relationships or material transactions with the Company; standard indemnification agreement entered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125507,"accession_number":"0001193125-25-314249","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Dyne Therapeutics prices upsized $350M public offering at $18.44/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 18,980,478 shares at $18.44/share; gross proceeds $350M.","Underwriters granted 30-day option for additional 2,847,071 shares.","Net proceeds estimated at ~$328.5M ($377.9M if option exercised).","Also borrowed $50M second tranche under Hercules Loan Agreement.","Cash runway extended into Q1 2028 with combined resources."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125506,"accession_number":"0001193125-25-311221","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["2.03","1.01"],"status":"ready","headline":"Dyne Therapeutics borrows $50M under amended Hercules loan; up to $125M additional available","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $50M second tranche under amended Loan and Security Agreement with Hercules Capital.","Two additional tranches of up to $75M available upon achieving clinical, regulatory, and commercial milestones.","Final tranche of up to $50M subject to Lenders' investment committee approval.","Maturity July 1, 2030; interest at WSJ Prime + 2.45% (floor 7.50%); interest-only until July 2028.","Collateral includes first-priority security interest in substantially all assets, including IP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125505,"accession_number":"0001193125-25-310516","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Dyne Therapeutics: DELIVER trial meets primary endpoint; dystrophin 5.46% of normal; BLA submission Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: muscle content-adjusted dystrophin expression 5.46% of normal (p<0.0001), replicating 7-fold increase from MAD portion.","Functional improvement across all six prespecified endpoints; two (TTR Velocity, 10MWR) nominal p<0.05; lung function preserved vs placebo decline.","Long-term data up to 24 months show sustained functional improvement across all assessed endpoints (TTR Velocity, 10MWR, NSAA, SV95C, PUL2.0, FVC%p).","Safety favorable: 1,441 doses administered; 113 patient-years; no related serious TEAEs in REC; two related serious TEAEs in OLE/LTE resolved.","BLA for U.S. Accelerated Approval planned Q2 2026; global Phase 3 initiation Q2 2026; potential U.S. launch Q1 2027 assuming Priority Review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125504,"accession_number":"0001193125-25-266979","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Therapeutics Q3 net loss $108M; DMD topline data expected Dec 2025; DM1 enrollment delayed to early Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $108.0M ($0.76/share) vs $97.1M ($0.96/share) in Q3 2024; R&D $97.2M, G&A $16.7M.","Cash $791.9M; reaffirms runway into Q3 2027 covering first commercial launch and BLA submissions.","Topline data from DELIVER REC (z-rostudirsen in DMD) on track for Dec 2025; BLA submission Q2 2026, launch Q1 2027.","ACHIEVE REC enrollment (z-basivarsen in DM1) now expected early Q2 2026 (shift from Q4 2025) due to US site activation.","FDA granted Breakthrough Therapy Designation for z-rostudirsen in Aug 2025; one-year DM1 data presented at WMS."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125503,"accession_number":"0001193125-25-228317","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-10-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Dyne Therapeutics elects Brian Posner as Class III director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian Posner elected to Board effective Oct 1, 2025; term runs until 2026 annual meeting.","Posner deemed independent under Nasdaq rules; no committee appointments.","Received option to purchase 70,000 shares at $12.50 strike, vesting monthly over three years.","Annual cash compensation of $45,000 plus standard equity grants under director program.","No family relationships or transactions with company officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142246,"accession_number":"0000950170-25-101620","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne MD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Breakthrough Therapy Designation to DYNE-251 for DMD amenable to exon 51 skipping.","Designation based on DELIVER trial data showing sustained functional improvement over 18 months.","DYNE-251 now joins DYNE-101 (DM1) as Dyne's second compound to receive this designation.","Registrational expansion cohort data expected late 2025; BLA submission for accelerated approval anticipated early 2026.","Benefits include rolling review, Priority Review eligibility, and enhanced FDA support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142245,"accession_number":"0000950170-25-099184","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Q2 net loss $110.9M extends cash runway into Q3 2027 on $215M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $110.9M ($0.97/sh) vs $65.1M ($0.70) in Q2 2024; R&D expenses $99.2M.","Cash $683.9M; July offering net $215.2M; Hercules $100M initial loan; runway into Q3 2027.","DYNE-251 DMD registrational cohort enrolled (32 pts); data late 2025; potential BLA early 2026.","DYNE-101 DM1 FDA Breakthrough Therapy; 60-pt cohort enrollment Q4 2025; data mid-2026; BLA late 2026.","Hercules $275M senior secured loan; 5 tranches; milestones-based drawdown; final tranche subject to approval."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142244,"accession_number":"0001193125-25-154057","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Dyne Therapeutics prices $200M public offering of 24.2M shares at $8.25/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $200M; net proceeds ~$187M ($215.2M if underwriters exercise 30-day option for 3.6M additional shares).","Closing expected July 2, 2025; all shares sold by the company, resulting in dilution.","Cash runway extended into Q3 2027 inclusive of June 2025 $100M term loan from Hercules Capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160258,"accession_number":"0001193125-25-152652","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Dyne Therapeutics enters $275M loan agreement with Hercules Capital; $100M funded immediately","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial tranche of $100M funded on June 27, 2025; additional tranches up to $175M available upon milestones and lender discretion.","Interest rate of WSJ Prime + 2.45% (floor 7.50%); maturity July 1, 2030; interest-only until July 1, 2028, extendable.","First-priority security interest on substantially all assets including IP; covenants include minimum cash and minimum net product revenue post-approval of DYNE-101 or DYNE-251.","Prepayment penalty ranges from 0.75% to 2.0% of prepaid amount; end-of-term charge of 5.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160257,"accession_number":"0001193125-25-141739","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA Breakthrough Therapy Designation for DYNE-101 in DM1; revised Accelerated Approval path","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Breakthrough Therapy Designation to DYNE-101 for myotonic dystrophy type 1 (DM1).","Revised ACHIEVE trial protocol submitted with vHOT as primary endpoint (60 patients, 3:1 randomization).","Enrollment in Registrational Expansion Cohort expected to complete Q4 2025; data mid-2026, submission late 2026.","New 12-month data: sustained vHOT improvement of 3.3 sec at 6 months; QMT strength improved 10% at 6 mo, 20% at 12 mo.","Cash $677.5M as of March 31, 2025; runway extended into Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160256,"accession_number":"0000950170-25-082317","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Dyne Therapeutics shareholders elect Hurwitz, Kersten; approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Edward Hurwitz elected with 62.9M votes for, 27.4M withheld; Dirk Kersten with 58.3M for, 32.0M withheld.","Non-binding advisory say-on-pay approved: 74.4M for, 15.8M against, 81.6K abstain.","Stockholders recommend advisory vote on executive compensation every year (90.2M votes); company will hold annual say-on-pay.","Ratification of Deloitte & Touche LLP as independent auditor for FY2025: 105.6M for, 19.8K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160255,"accession_number":"0000950170-25-066396","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Q1 net loss $115.4M ($1.05/sh); advances DM1 & DMD toward 2026-2027 approvals","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $677.5M; expects funding operations into H2 2026.","R&D expenses $106.4M (Q1 2025) vs $44.5M (Q1 2024); net loss widened.","ACHIEVE Registrational Expansion Cohort for DYNE-101 (DM1) initiated; up to 48 patients; data H1 2026.","DELIVER Registrational Expansion Cohort for DYNE-251 (DMD) fully enrolled (32 patients); data late 2025.","New CFO (Erick Lucera), CBO (Vikram Ranade), CSO (Ranjan Batra); Oxana Beskrovnaya named CIO."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178553,"accession_number":"0001193125-25-058979","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Dyne Therapeutics appoints Erick Lucera as CFO; outgoing CFO Richard Scalzo to consult","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erick Lucera named CFO and Treasurer, effective March 31, 2025; previously CFO of Editas Medicine and AVEO Pharmaceuticals.","Lucera receives base salary $520k, bonus up to 40%, and inducement equity: 214,500 stock options + 66,100 RSUs.","Richard Scalzo steps down as SVP Finance & Treasurer same date; will provide consulting services for up to 6 months.","Scalzo's unvested equity to continue vesting during consultancy; stock option exercise period extended to 6 months post-consulting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178552,"accession_number":"0000950170-25-028369","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Therapeutics reports FY2024 net loss $317.4M; advances DYNE-101 and DYNE-251 toward accelerated approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA granted Fast Track designation for DYNE-101 in DM1; registrational expansion cohort enrollment planned mid-2025.","DYNE-251 in DMD: registrational expansion cohort enrollment targeted Q1 2025; data expected late 2025.","Cash and equivalents $642.3M at Dec 31, 2024; plus $140.6M from ATM in Q1 2025; runway into H2 2026.","Q4 2024 net loss $89.5M ($0.88 per share) vs $66.6M (Q4 2023); R&D expenses $81.8M (Q4 2024).","Potential U.S. accelerated approval submissions for DYNE-101 in H1 2026 and DYNE-251 in early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178551,"accession_number":"0001193125-25-004057","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Dyne reports $642M cash, positive DYNE-101 DM1 data, H1 2026 submission path","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents, and marketable securities ~$642M as of Dec 31, 2024 (unaudited).","DYNE-101 in DM1: 6.8 mg/kg Q8W dose showed robust splicing correction at 3 months and sustained functional improvements.","DYNE-101 safety: 855 doses administered, >72 patient-years follow-up; no related serious TEAEs.","Plans ~32-patient Registrational Expansion Cohort for DYNE-101 in mid-2025; U.S. accelerated approval submission targeted H1 2026.","DYNE-251 for DMD exon 51: FDA supports dystrophin as surrogate endpoint; data from 20 mg/kg cohort expected late 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195219,"accession_number":"0001193125-24-255269","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Dyne upsizes ATM offering from $200M to $300M; $101.2M already sold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to sell up to $300M common stock via ATM with Jefferies, up from $200M.","As of Nov 12, 2024, aggregate gross proceeds of ~$101.2M already sold under prior $200M program.","New supplement replaces prior prospectus; no further sales will be made under the old one.","Shares registered under existing shelf registration statement; legal opinion included as exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195218,"accession_number":"0000950170-24-124583","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Therapeutics reports Q3 net loss $97.1M; IND cleared for DYNE-101; registrational cohort enrolling for DYNE-251","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $97.1M ($0.96 per share) vs $60.2M ($0.99) in Q3 2023; R&D expenses rose to $92.8M from $55.3M.","FDA cleared IND for DYNE-101 in DM1; Phase 1/2 ACHIEVE trial fully enrolled through 6.8 mg/kg Q8W cohort (56 participants).","New ACHIEVE data (splicing, vHOT, functional measures) expected early January 2025; pursuing accelerated approval using splicing surrogate.","Enrolling 20 mg/kg Q4W registrational cohort (n=32) in DELIVER trial for DMD exon 51; seeks accelerated approval based on dystrophin.","Cash $723.7M at Sept 30, 2024; expected to fund operations at least into H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211478,"accession_number":"0001193125-24-211534","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Dyne Therapeutics initiates registrational cohorts after positive Phase 1/2 DELIVER data; leadership changes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DYNE-251 (20 mg/kg Q4W) showed mean absolute dystrophin 3.71% of normal (unadjusted), >10x eteplirsen's 0.3% (cross-trial caution).","Functional improvement in NSAA, SV95C (met EMA MCID), 10-MWR, Time to Rise from Floor; 10 mg/kg cohort improved from 6 to 12 months.","Safety: favorable profile; no related SAEs except two at 40 mg/kg (resolved); >675 doses, >50 patient-years follow-up.","Leadership: CMO Wildon Farwell resigned; hired Doug Kerr as CMO, Johanna Friedl-Naderer as CCO, Lucia Celona as CHRO; CBO and COO also resigning.","Plans to update path to registration for DYNE-251 and DYNE-101 by end of 2024; ACHIEVE trial safety favorable up to 6.8 mg/kg Q8W."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211477,"accession_number":"0000950170-24-095537","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Q2 net loss $65.1M, cash $778.8M; ACHIEVE/DELIVER data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 net loss $65.1M ($0.70/sh) vs $64.9M ($1.08/sh) in Q2 2023.","Cash, cash equivalents and marketable securities $778.8M, funded at least into H2 2026.","Completed $374.3M public offering (12.075M shares at $31.00) in May 2024.","DYNE-101 in DM1 showed splicing correction and functional improvement; DYNE-251 in DMD showed dystrophin expression exceeding eteplirsen at 6 months.","Company plans to provide registration path update for both programs by year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230132,"accession_number":"0000950170-24-064700","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Dyne Therapeutics shareholders elect three Class I directors, ratify Deloitte as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Carlo Incerti, M.D. elected with 61,028,245 votes for, 8,752,856 withheld, 5,235,919 broker non-votes.","Catherine Stehman-Breen, M.D. elected with 55,026,485 votes for, 14,325,362 withheld, 5,665,173 broker non-votes.","John G. Cox elected with 69,763,860 votes for, 32,767 withheld, 5,220,393 broker non-votes.","Ratification of Deloitte & Touche as independent auditor for FY2024 passed with 74,962,217 for, 12,377 against, 42,426 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230131,"accession_number":"0001193125-24-144470","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Dyne Therapeutics prices $325.5M public offering of 10.5M shares at $31.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $325.5M; net proceeds estimated at $305.4M ($351.4M if underwriters' option is fully exercised).","Underwriters include Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities; closing expected May 24, 2024.","Company granted 30-day option for underwriters to purchase an additional 1.575M shares at the same price.","Net proceeds plus existing cash expected to fund operations at least into the second half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230130,"accession_number":"0001193125-24-142232","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Dyne: DYNE-101 achieves 27% splicing correction at 3 months; DYNE-251 shows 3.22% dystrophin expression in DMD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DYNE-101 5.4 mg/kg Q8W showed 27% mean splicing correction across 22-gene panel at 3 months, all participants responded.","DYNE-101 improved myotonia (vHOT) by 4.5 sec at 3 months (5.4 mg/kg) and 4.4 sec at 12 months (1.8 mg/kg Q4W).","DYNE-251 10 mg/kg monthly achieved mean unadjusted dystrophin 3.22% (7.64% muscle-adjusted) vs 0.30% for weekly eteplirsen.","DYNE-251 showed trends in functional endpoints: NSAA, SV95C, 10-Meter Walk/Run, and Time to Rise at 6 months.","Favorable safety for both; FDA accelerated approval pathways confirmed; registration pathway update expected by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230129,"accession_number":"0000950170-24-052142","cik":1818794,"company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dyne Therapeutics Q1 net loss $65.6M; cash $453.5M; clinical trials on track for H2 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $65.6M ($0.81 per share) vs $44.2M ($0.78) in Q1 2023.","Cash, equivalents and marketable securities $453.5M; expects funding through 2025.","R&D expenses $44.5M (up 19% YoY); G&A expenses $24.6M (up 211% YoY) largely due to new CEO.","John Cox appointed CEO and President in March 2024.","Phase 1/2 ACHIEVE (DM1) and DELIVER (DMD) trials progressing; additional data expected H2 2024 with registrational cohorts by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3040120700.9867845,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}